固态电解质中间相(SEI)层是锂离子电池(LIB)的关键元素,它能够稳定运行并显着影响包括寿命在内的循环性能。在这里,我们介绍化学软SEI形成添加剂的概念,该概念是通过引入已为人熟知的SEI-former的芳香环基衍生物制成的,以使其具有化学软性,从而生成1,3,2-苯并二氧杂硫醇2,2-二氧化物(DTDPh ),3 H -1,2-苯并硫氧杂2,2-二氧化物(PSPh)和1,4,2-苯并二氧嘧啶2,2-二氧化物(PSOPh)。基于计算DFT的比较可预测有关早期还原过程和受控还原过程的前景。这些预测已通过针对适当的添加剂还原电位的基础电化学研究得到证实,即在任何电解质溶剂或盐分解之前。此外,预测了SEI前体的分解路径,并将最终产品与在LIB单元中形成的SEI层的光谱数据进行了比较。最终形成的SEI层在改善的容量保持性,改善的库仑效率和降低的石墨/电解质/ LFP全电池电阻方面表现出非常好的性
Laleh, Ahmed; Ranson, Richard; Tillett, John G., Journal of the Chemical Society. Perkin transactions II, 1980, p. 610 - 615
作者:Laleh, Ahmed、Ranson, Richard、Tillett, John G.
DOI:——
日期:——
Marckwald; Frahne, Chemische Berichte, 1898, vol. 31, p. 1861
作者:Marckwald、Frahne
DOI:——
日期:——
KAPPA OPIOID RECEPTOR AGONISTS
申请人:Sasmal Pradip Kumar
公开号:US20130303525A1
公开(公告)日:2013-11-14
The present invention relates to a series of substituted compounds having the general formula (I), including their stereoisomers and/or their pharmaceutically acceptable salts. (I) Wherein A, m, R1s, R2, R3, R4 are as defined herein. This invention also relates to methods of making these compounds including intermediates. The compounds of this invention are effective at the kappa (κ) opioid receptor (KOR) site. Therefore, the compounds of this invention are useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of central nervous system disorders (CNS), including but not limited to acute and chronic pain, and associated disorders, particularly functioning peripherally at the CNS.
Flame Retardants For Lithium Batteries
申请人:Albemarle Corporation
公开号:US20220407110A1
公开(公告)日:2022-12-22
This invention provides nonaqueous electrolyte solutions for lithium batteries which contain one or more brominated flame retardants. The nonaqueous electrolyte solutions comprise a) a liquid electrolyte medium; b) a lithium-containing salt; and c) at least one brominated flame retardant. The brominated flame retardant is present in the electrolyte solution in a flame retardant amount.
COMPOUNDS AND METHODS OF TREATING RNA-MEDIATED DISEASES
申请人:Arrakis Therapeutics, Inc.
公开号:US20220281860A1
公开(公告)日:2022-09-08
The present invention provides compounds, compositions thereof, and methods of using the same.